RVMD

Insider Trades

Name	Value	Action	Price	Current Price
Anders JackChief Financial Officer $1.6M9.5k shares SellJun 24, 2026 $168.20 $153.00
Anders JackChief Financial Officer $956k5.7k shares SellJun 24, 2026 $169.24 $153.00
Anders JackChief Financial Officer $762k4.6k shares SellJun 24, 2026 $167.35 $153.00
Anders JackChief Financial Officer $51k300 shares SellJun 24, 2026 $170.32 $153.00
Anders JackChief Financial Officer $274k2.8k shares SellMar 17, 2026 $99.48 $153.00
Anders JackChief Financial Officer $980k10k shares SellJan 7, 2026 $98.00 $153.00

News

seekingalpha.comRevolution Medicines: Strong Data, Big Market (Rating Upgrade)seekingalpha.comJun 13

fool.comCan Revolution Medicines Be a Game-Changer Stock?fool.comJun 11

zacks.comWhy Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?zacks.comJun 5

fool.comHealthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotechfool.comJun 5

fool.comRevolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.fool.comJun 5

Trade RVMD

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

CEO: Mark A. Goldsmith
IPO Date: Feb 13, 2020

Market Data

Open: $160.94
High: $164.76
Low: $158.44
Volume: 4M
Avg Volume: 3.2M
52W High: $166.50
52W Low: $34.00

Valuation

Market Cap: $35B
Enterprise Value: $35B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-914M
Revenue: $0
Net Income: $-1.1B
Cash: $384M
Debt: $159M

Events

EarningsAug 5

EPS est. -1.96073